Cornelia Ursula Kunz

Generating author description...

All published works

Action	Title	Year	Authors
+	Two-stage group-sequential designs with delayed responses – what is the point of applying corresponding methods?	2024	Stephen Schüürhuis Gernot Wassmer Meinhard Kieser Friedrich Pahlke Cornelia Ursula Kunz Carolin Herrmann
+ PDF Chat	Considerations for the planning, conduct and reporting of clinical trials with interim analyses	2024	Elina Asikanius Benjamin Hofner Lisa V. Hampson Gernot Wassmer Christopher Jennison Tobias Mielke Cornelia Ursula Kunz Kaspar Rufibach
+ PDF Chat	A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart	2024	Stephen Schüürhuis Frank Konietschke Cornelia Ursula Kunz
+ PDF Chat	Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions	2024	Cornelia Ursula Kunz Sergey Tarima Gary L. Rosner Richard Emsley Madeline Bauer Christopher Jennison James L. Rosenberger Nigel Stallard Sarah Zohar Nancy Flournoy
+ PDF Chat	Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints	2023	Dario Zocholl Cornelia Ursula Kunz Geraldine Rauch
+ PDF Chat	Should the two‐trial paradigm still be the gold standard in drug assessment?	2022	Stella Jinran Zhan Cornelia Ursula Kunz Nigel Stallard
+ PDF Chat	A systematic review of the “promising zone” design	2020	Julia Edwards Stephen J. Walters Cornelia Ursula Kunz Steven A. Julious
+	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?	2020	Cornelia Ursula Kunz Silke Jörgens Frank Bretz Nigel Stallard Kelly Van Lancker Dong Xi Sarah Zohar Christoph Gerlinger Tim Friede
+	Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?	2020	Cornelia Ursula Kunz Silke Jörgens Frank Bretz Nigel Stallard Kelly Van Lancker Dong Xi Sarah Zohar Christoph Gerlinger Tim Friede
+	Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?	2020	Cornelia Ursula Kunz Silke Jörgens Frank Bretz Nigel Stallard Kelly Van Lancker Dong Xi Sarah Zohar Christoph Gerlinger Tim Friede
+ PDF Chat	Interim analysis incorporating short‐ and long‐term binary endpoints	2019	Julia Niewczas Cornelia Ursula Kunz Franz König
+ PDF Chat	Confidence regions for treatment effects in subgroups in biomarker stratified designs	2018	Fang Wan Cornelia Ursula Kunz Thomas Jaki
+ PDF Chat	An alternative method to analyse the biomarker‐strategy design	2018	Cornelia Ursula Kunz Thomas Jaki Nigel Stallard
+ PDF Chat	<b>OneArmPhaseTwoStudy</b>: An <i>R</i> Package for Planning, Conducting, and Analysing Single-Arm Phase II Studies	2017	Meinhard Kieser Marius Wirths Stefan Englert Cornelia Ursula Kunz Geraldine Rauch
+	Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations	2016	Cornelia Ursula Kunz Nigel Stallard Nick Parsons Susan Todd Tim Friede
+ PDF Chat	Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial	2015	Nigel Stallard Cornelia Ursula Kunz Susan Todd Nick Parsons Tim Friede
+ PDF Chat	Two-stage phase II oncology designs using short-term endpoints for early stopping	2015	Cornelia Ursula Kunz James Wason Meinhard Kieser
+ PDF Chat	Data‐driven treatment selection for seamless phase II/III trials incorporating early‐outcome data	2014	Cornelia Ursula Kunz Tim Friede Nick Parsons Susan Todd Nigel Stallard
+ PDF Chat	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints	2014	Cornelia Ursula Kunz Tim Friede Nick Parsons Susan Todd Nigel Stallard
+	Estimation of secondary endpoints in two‐stage phase II oncology trials	2012	Cornelia Ursula Kunz Meinhard Kieser
+	Curtailment in single‐arm two‐stage phase II oncology trials	2012	Cornelia Ursula Kunz Meinhard Kieser
+	Simon's Minimax and Optimal and Jung's Admissible Two-stage Designs with or without Curtailment	2011	Cornelia Ursula Kunz Meinhard Kieser
+	Optimal Two-stage Designs for Single-arm Phase II Oncology Trials with Two Binary Endpoints	2010	Cornelia Ursula Kunz Meinhard Kieser

Common Coauthors

Coauthor	Papers Together
Nigel Stallard	10
Tim Friede	7
Meinhard Kieser	7
Nick Parsons	4
Sarah Zohar	4
Susan Todd	4
Christoph Gerlinger	3
Kelly Van Lancker	3
Frank Bretz	3
Silke Jörgens	3
Dong Xi	2
Gernot Wassmer	2
Christopher Jennison	2
Thomas Jaki	2
Geraldine Rauch	2
Stephen Schüürhuis	2
Kaspar Rufibach	1
Julia Niewczas	1
Benjamin Hofner	1
James L. Rosenberger	1
Stephen J. Walters	1
Elina Asikanius	1
Sergey Tarima	1
Fang Wan	1
Madeline Bauer	1
Frank Konietschke	1
Dong Xi	1
Stella Jinran Zhan	1
Gary L. Rosner	1
Steven A. Julious	1
Stefan Englert	1
James Wason	1
Dario Zocholl	1
Nancy Flournoy	1
Carolin Herrmann	1
Tobias Mielke	1
Marius Wirths	1
Franz König	1
Julia Edwards	1
Friedrich Pahlke	1
Richard Emsley	1
Lisa V. Hampson	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Group Sequential Tests for Delayed Responses (with discussion)	2012	Lisa V. Hampson Christopher Jennison	7
+ PDF Chat	Optimal two-stage designs for phase II clinical trials	1989	Richard Simon	7
+ PDF Chat	Adaptive Sample Size Calculations in Group Sequential Trials	1999	Walter Lehmacher Gernot Wassmer	6
+	Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis	2011	Tim Friede Nick Parsons Nigel Stallard S. Todd E. Valdes Marquez Jeremy Chataway Richard Nicholas	6
+	A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information	2010	Nigel Stallard	6
+	Interim analysis of continuous long‐term endpoints in clinical trials with longitudinal outcomes	2003	Sally Galbraith Ian C. Marschner	5
+	Designed Extension of Studies Based on Conditional Power	1995	Michael A. Proschan Sally Hunsberger	5
+	Recursive Combination Tests	2002	Werner Brannath Martin Posch Péter Bauer	5
+ PDF Chat	Adaptive sample size modification in clinical trials: start small then ask for more?	2015	Christopher Jennison Bruce W. Turnbull	4
+	An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†	2010	Martin Jenkins Andrew Stone Christopher Jennison	4
+	Evaluation of Experiments with Adaptive Interim Analyses	1994	Péter Bauer Karl Kohne	4
+	A two‐stage phase II trial design utilizing both primary and secondary endpoints	2007	Xun Lin Randy Allred Glen Andrews	4
+	Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches	2001	Hans‐Helge Müller H. Schäfer	4
+	A New Clinical Trial Design Combining Phases 2 and 3: Sequential Designs with Treatment Selection and a Change of Endpoint	2005	Susan Todd Nigel Stallard	4
+	Admissible two‐stage designs for phase II cancer clinical trials	2004	Sin‐Ho Jung Taiyeong Lee KyungMann Kim Stephen L. George	4
+	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts	2006	Frank Bretz Heinz Schmidli Franz König Amy Racine Willi Maurer	4
+ PDF Chat	Optimal three-stage designs for phase II cancer clinical trials	1997	T. Timothy Chen	4
+	Optimal two-stage designs for single arm Phase II cancer trials	2002	Jonathan J. Shuster	3
+	A Multiple Testing Procedure for Clinical Trials	1979	Peter C. O’Brien Thomas R. Fleming	3
+ PDF Chat	Testing and estimation in flexible group sequential designs with adaptive treatment selection	2005	Martin Posch Franz Koenig Michael Branson Werner Brannath Cornelia Dunger‐Baldauf Péter Bauer	3
+	Optimal Two-stage Designs for Single-arm Phase II Oncology Trials with Two Binary Endpoints	2010	Cornelia Ursula Kunz Meinhard Kieser	3
+ PDF Chat	Interim analysis incorporating short‐ and long‐term binary endpoints	2019	Julia Niewczas Cornelia Ursula Kunz Franz König	3
+	A conditional error function approach for subgroup selection in adaptive clinical trials	2012	Tim Friede Nick Parsons Nigel Stallard	3
+ PDF Chat	Evaluating futility of a binary clinical endpoint using early read‐outs	2019	Kelly Van Lancker An Vandebosch Stijn Vansteelandt Filip De Ridder	3
+	Stochastically curtailed phase II clinical trials	2006	A. O. Ayanlowo David T. Redden	3
+ PDF Chat	A Comparison of Methods for Treatment Selection in Seamless Phase II/III Clinical Trials Incorporating Information on Short-Term Endpoints	2014	Cornelia Ursula Kunz Tim Friede Nick Parsons Susan Todd Nigel Stallard	3
+	Improving interim decisions in randomized trials by exploiting information on short‐term endpoints and prognostic baseline covariates	2020	Kelly Van Lancker An Vandebosch Stijn Vansteelandt	3
+	Design and analysis of group sequential tests based on the type I error spending rate function	1987	KyungMann Kim David L. DeMets	3
+	Effects of Assumption Violations on Type I Error Rate in Group Sequential Monitoring	1992	Michael A. Proschan Dean Follmann Myron A. Waclawiw	3
+	Designs for Group Sequential Phase II Clinical Trials	1987	M N Chang Terry M. Therneau H. Samuel Wieand S. Stephen	3
+	The sequential analysis of repeated binary responses: a score test for the case of three time points	2005	M. R. Sooriyarachchi John Whitehead Anne Whitehead Kim Bolland	3
+	Adaptive designs for confirmatory clinical trials	2009	Frank Bretz Franz Koenig Werner Brannath Ekkehard Glimm Martin Posch	3
+ PDF Chat	Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases	2016	Tim Friede Christian Röver Simon Wandel Beat Neuenschwander	3
+	On closed testing procedures with special reference to ordered analysis of variance	1976	Ruth Marcus Eric Peritz K. R. Gabriel	3
+ PDF Chat	Proper inference from Simon's two‐stage designs	2007	Tatsuki Koyama Heidi Chen	3
+	An optimal two-stage phase II design utilizing complete and partial response information separately	2002	Katherine S. Panageas Alex Smith Mithat Gönen Paul B. Chapman	3
+	Randomized Phase II Trials: Inevitable or Inadvisable?	2010	Hui Gan Axel Grothey Gregory R. Pond Malcolm J. Moore Lillian L. Siu Daniel J. Sargent	3
+	Group sequential methods in the design and analysis of clinical trials	1977	Stuart J. Pocock	3
+	A design of phase II cancer trials using total and complete response endpoints	2005	Ying Lü Hua Jin Kathleen R. Lamborn	3
+ PDF Chat	Adaptive increase in sample size when interim results are promising: A practical guide with examples	2010	Cyrus R. Mehta Stuart J. Pocock	3
+	Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses	2000	Lin Shang T. Timothy Chen	3
+	Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration	2010	Werner Brannath Hans Ulrich Burger Ekkehard Glimm Nigel Stallard Marc Vandemeulebroecke Gernot Wassmer	3
+	Interim monitoring of clinical trials based on long-term binary endpoints	2001	Simone Marschner Simone L. Becker	3
+	Group Sequential and Confirmatory Adaptive Designs in Clinical Trials	2016	Gernot Wassmer Werner Brannath	3
+	Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls	2009	Jonathan A C Sterne Ian R. White John B. Carlin Michael Spratt Patrick Royston Michael G. Kenward Angela Wood James R. Carpenter	2
+	Overrunning and underrunning in sequential clinical trials	1992	John Whitehead	2
+	Interim analysis: The alpha spending function approach	1994	David L. DeMets K. K. Gordon Lan	2
+	Key multiplicity issues in clinical drug development	2012	Alex Dmitrienko Ralph B. D’Agostino Mohammad F. Huque	2
+	Incorporating Data Received after a Sequential Trial Has Stopped into the Final Analysis: Implementation and Comparison of Methods	2003	M. R. Sooriyarachchi John Whitehead Tatsuru Matsushita Kim Bolland Anne Whitehead	2
+	Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials	1995	John Bryant Roger Day	2